SCHEMBL11943018

SCHEMBL11943018

CC(C)Sc1c(N2CCN(Cc3cccs3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 11/20 0.51
▸ DRD3 P35462 8/20 0.51
▸ DRD2 P14416 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ DRD5 P21918 4/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ DCTPP1 Q9H773 2/20 0.40
▸ SMO Q99835 1/20 0.40
▸ DRD1 P21728 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943334 0.84 DRD4 (0.52) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943029 0.82 KDM4E (0.40) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943023 0.80 ALDH1A1 (0.44) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943065 0.80 SMO (0.53) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943071 0.80 SMO (0.45) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943070 0.80 MAPT (0.43) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943064 0.79 SMN1; SMN2 (0.43) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943022 0.78 MAPT (0.41) DRD4DRD3DRD2SMN1; SMN2ALDH1A1
SCHEMBL11943066 0.78 SMO (0.51) ALDH1A1POLBMAPTLMNAKDM4E
SCHEMBL11943472 0.77 DRD4 (0.51) DRD4DRD3DRD2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA DRD4 4875/4885DRD3 4829/4885DRD2 4876/4885
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 DRD4 4876/4885DRD3 4865/4885DRD2 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback